Byterna Therapeutics Selected for '2025 China Biopharma Leaders 100' with Innovative Circular mRNA and AI Platforms Paving the Way for Next-Generation Digital Healthcare

(Source:Sunshine Nova）

The following article is from Byterna Therapeutics, authored by Byterna Therapeutics.

Recently, the 2025 Shanghai Biomedical Financing and Investment Summit & Fudan Biomedical Innovation and Development Forum was successfully held in Shanghai, and the much-anticipated "2025 China Biomedical Leaders 100" list was officially released.

Byterna Therapeutics, a partner of Sunshine Novo, has successfully been selected into the "Top 100 Leaders" in the digital healthcare field due to continuous breakthroughs in its three core technology platforms: AI-driven intelligent design of nucleic acid drugs, traceless and modifiable circular mRNA technology, and cell subpopulation-specific in vivo targeted delivery. This reflects the high recognition from authoritative institutions and the capital market of the company's innovative strength, technological value, industrialization potential, and industry influence.

Authoritative Endorsement, Value Benchmark

"The Leader 100" list was initiated by the Shanghai Biomedical Science and Technology Industry Promotion Center, in collaboration with Shanghai Biomedical Fund, Shanghai Guotou Xiandao, Qiming Venture Capital, Boyuan Capital,Cathay Pacific Healthcare, Shanghai Frontier, Xinzhe Zhixing Port, ATLATL Innovation and Research Center, and other numerous ecosystem collaborators, along with expert senior investment institutions, conducted a comprehensive evaluation and selection from dimensions such as business strength, technological innovation capability, clinical and industrial transformation prospects, organizational and governance capacity, ultimately forming a benchmark list of companies with industry trendsetting significance. This list not only reflects the independent review and cross-verification by multiple professional organizations but also provides authoritative reference for industry and capital synergy.

Technology Leadership, Building Core Competitiveness

Byterna Therapeutics focuses on the development of novel drugs for circular mRNA immunotherapy with a trinity technology system of "AI × Circular RNA × Targeted Delivery":

AI Nucleic Acid Drug Intelligent Design: Building an end-to-end intelligent engine from target selection, molecule generation to multi-dimensional scoring and optimization, improving the efficiency and hit rate of lead discovery, and shortening the R&D cycle.

Scarless Modifiable Circular mRNA Technology: Achieving "scarless" circular mRNA construction based on the highly efficient PIE (permuted intron–exon) platform, marking the industry's first breakthrough in chemically modified circular mRNA technology. It balances expression strength, persistence, and low immunogenicity while establishing standardized and scalable manufacturing and purification processes.

Cell Subpopulation-Level Specific In Vivo Targeted Delivery: Focusing on the engineering of actively targeted LNP carriers, we iteratively develop a scalable and industrially viable technical solution capable of precise delivery at the cell subpopulation level (e.g., T cells) in vivo. This lays the foundation for non-integrative, controllable in vivo CAR therapy and deeply aligns with the R&D vision of "achieving cellular therapeutic effects through nucleic acid drug modalities."

Relying on the aforementioned platform capabilities, Byterna Therapeutics has formed differentiated advantages in the safety, controllability, and industrial feasibility of circular mRNA therapy, promoting the deep application of circular mRNA technology in cellular immunotherapy and precision medicine scenarios.

Industry Recognition, Ecosystem Resonance

The release of the list coincides with a period of回暖 in the biopharmaceutical capital market and持续优化的 policy environment. The industry is transitioning from "going it alone" to "collaborative win-win," with innovation models evolving from "generalized innovation" to "selective premium." The inclusion of Byterna Therapeutics not only represents authoritative recognition of阶段性成果, but also affirms its ability to achieve continuous breakthroughs in cutting-edge fields and its openness to collaboration. The company will deepen cooperation with industrial and academic partners both in China and internationally, accelerate technology validation and clinical translation, and jointly enhance the global competitiveness of China's biopharmaceutical sector.

Byterna Therapeutics is an innovative biopharmaceutical company centered on AI and circular mRNA technology, focusing on the development of novel immunotherapies based on circular mRNA. Leveraging a leading AI algorithm platform, foundational circular mRNA technology, and an in vivo CAR-T new drug platform, we are committed to delivering "safe, effective, accessible, and affordable (SEAA)" in vivo CAR-T cell therapy in the form of nucleic acid drugs. Our mission is to unlock the full therapeutic potential of CAR-T therapies in autoimmune diseases and cancer, benefiting patients worldwide.